Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Prestige's OTC brands grow: Prestige Brands Holdings reports flat quarterly net sales - $73.2 million compared to $73.5 million in the year-ago period - during its Aug. 5 fiscal 2010 first-quarter earnings call. While the Irvington, N.Y.-based firm's household product revenues declined by 5 percent, its over-the-counter revenues were at $40.3 million, a 3 percent increase from the previous Q1. Increases in Chloraseptic, Clear Eyes, Little Remedies, The Doctor's and Allergen Block brands drove sales. The Little Remedies pediatrics line was up 40 percent and The Doctor's dental devices rose 47 percent, CEO Mark Pettie said during the call. The firm reported increased sales of Cutex nail polish remover, which were "partially offset by a decline on Denorex shampoo." Net income for the quarter was $8.3 million, a 6.4 percent boost from the previous year's $7.8 million, which the firm attributed mainly to a lower interest expense of $5.7 million for the quarter, $3 million lower than first quarter 2008

You may also be interested in...



Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares

In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.

Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares

In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.

Drugstore.com plots additional microsites

The e-retailer will launch five to eight targeted microsites in 2010, including one potentially geared toward vitamins. All drugstore.com's microsites "will focus on attractive product categories with high margins," said CEO Dawn Lepore during an Oct. 20 third-quarter earnings call. The Bellevue, Wash., firm introduced 1www.sexualwellbeing.com in August and plans another microsite in 2009 (2"The Tan Sheet" Aug. 10, 2009). In the quarter ended Sept. 27, drugstore.com grew OTC net sales 16.5 percent to $71.3 million. Lepore highlighted vitamins and supplements, which grew 35 percent, and oral care, up 30 percent. Overall net sales jumped 10.2 percent to $96.8 million, though drugstore.com still reported a net loss of $1.6 million, compared to a net loss of $3.6 million in the year-ago quarter

Related Content

UsernamePublicRestriction

Register

PS103217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel